Viewpoint Molecular Targeting® Presents Preclinical Data from VMT- 𝛼 -NET, Theranostic in Development for the Treatment and Diagnosis of Neuroendocrine Tumors, at the Pacifichem 2021 Congress

Optimized 203Pb/212Pb image-guided alpha-particle radionuclide therapy for SST2R expressing tumors Preclinical data of VMT- alpha-NET demonstrated to significantly improve cell binding, tumor accumulation/retention and renal clearance of an SSTN analog VMT- alpha-NET...